Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study

What Was Tested

This observational study looks at Insulin Aspart and NPH Insulin (isophane).

Who Took Part

The abstract describes 30 people taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

This sub-analysis assessed patients switching from insulin glargine- or neutral protamine Hagedorn insulin-based basal-bolus insulin regimens to biphasic insulin aspart 30.

How the Study Was Run

In design terms this was an open-label study.

Being open-label, the Insulin Aspart study did not mask who received what.

A1chieve was an international, open-label, 24-week study in people with type 2 diabetes starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart.

What Was Measured

Topics PubMed links to this paper include Africa, Northern, Asia, Biomarkers, Biphasic Insulins, Blood Glucose, Diabetes Mellitus, Type 2 and Drug Substitution.

The authors tagged it with the keywords A(1)chieve, Basal-bolus insulin regimen, Biphasic insulin aspart and Type 2 diabetes.

What This Means in Plain Language

The paper is an open-label study of Insulin Aspart and NPH Insulin (isophane) in 30 people.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Primary care diabetes), a journal based in England.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page, all human trials.